Trevi Therapeutics, Inc. TRVI
13.92 USD +0.06 (+0.43%)
Nov 4, 2026, 1:06 PM EST
13.48 Day range 14.52
9.82 52-week range 20.22
- YTD
- +11.18%
- 1 year
- +28.18%
Analyst view
Price target (mean) 28.18 +102.5% upside
Now 13.92
- Target (low)
- 23.00
- Target (mean)
- 28.18
- Target (high)
- 40.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy2
- Buy9
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.133 | -0.18 – -0.11 | -0.08 | -66.3% | 0 | 0.0% | 10 |
| Next quarter | -0.143 | -0.20 – -0.07 | -0.06 | -138.3% | 0 | 0.0% | 10 |
| Current year | -0.479 | -0.58 – -0.34 | -0.32 | -49.7% | 0 | 0.0% | 10 |
| Next year | -0.577 | -0.76 – -0.40 | -0.479 | -20.5% | 0 | 0.0% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | Jones Trading | Maintained | Buy | Buy |
| Aug 7, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 7, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Jul 21, 2026 | BMO Capital | Initiated | Outperform | Outperform |
| Jul 20, 2026 | B. Riley Securities | Maintained | Buy | Buy |
| Jul 20, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 20, 2026 | Needham | Reiterated | Buy | Buy |
| May 6, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 6, 2026 | Needham | Maintained | Buy | Buy |
| Apr 17, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Mar 19, 2026 | Jones Trading | Maintained | Buy | Buy |
| Mar 18, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Mar 18, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Mar 18, 2026 | Needham | Maintained | Buy | Buy |
| Mar 9, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 8, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Dec 19, 2025 | Stifel | Maintained | Buy | Buy |
| Nov 20, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Nov 14, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Nov 14, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 14, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 14, 2025 | Clear Street | Maintained | Buy | Buy |
| Aug 21, 2025 | Morgan Stanley | Initiated | — | Overweight |
| Aug 8, 2025 | Raymond James | Maintained | Strong Buy | Strong Buy |
| Aug 8, 2025 | Needham | Maintained | Buy | Buy |
| Jul 1, 2025 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jun 2, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| May 28, 2025 | HC Wainwright & Co. | Initiated | — | Buy |